We are led by an experienced management team with a proven track record of developing scientific and medical products and bringing them to market.
Our Executive Committee assists the Chairman and CEO in our strategic and operational management.
Dr. Pierre-Henri Benhamou
Dr. Pierre-Henri Benhamou co-founded DBV Technologies in 2002, and has served as Chief Executive Officer from 2002 to the present and Chairman of board of directors since initial public offering on NYSE Euronext Paris in March 2012. With Pr. Christophe Dupont and Bertrand Dupont, he described for the first time and patented the epicutaneous method of immunotherapy and explored with the scientific team the wide range of applications of the method. Dr. Benhamou is a physician, specializing in pediatric gastroenterology. He has held numerous clinical and academic positions. He received the Altran Foundation Prize for Innovation in 2003 for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers and originated key scientific collaborations for us and has been instrumental in forming the Scientific Advisory Board. Dr. Benhamou holds an MD. in Medicine from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987. The board of directors believes that Dr. Benhamou’s leadership, deep knowledge of the company and scientific experience will allow him to drive DBV to the success.
Bertrand Dupont previously Chief Technical Officer has been appointed Senior Executive Vice President Technology since January 2015, and will be in charge of the continued development of the electrospray and upscaling of the production tools. He is a member of the Executive Committee.
From 1977 to 2002, Mr. Bertrand has served as a professor at the high school and at the university, teaching mechanics and robotics. In 1996, Mr. Dupont began to put his skills and expertise to use in biomedical research. Since 2000, he has been at the core of the development of the Viaskin® patches and applications. As Chief Industrial Officer, Mr. Dupont is a key figure in the development of the Viaskin® technology and the application systems. He is responsible for every technical development around the Viaskin® technology: design of the Viaskin® patch, in-house industrial patch filling processes, design and building of the machines which are developed by DBV Technologies. He is also responsible for the production of the finished product in the facilities of the CMO DBV partners. Mr. Dupont received an engineering degree from the School of Arts et Métiers of Paris in 1974 and an Aggregation in mechanical engineering in 1987.
David Schilansky has served as Chief Financial Officer since December 2011 and has been appointed as Chief Operating Officer in January 2015 to support the CEO in the implementation of DBV’s strategy. He supervises all financial work, human resources, general secretary, communication, investor relations as well as partnership and business development activities. He is a member of the Executive Committee.
From 2006 to 2011, Mr. Schilansky held various important positions at the Ipsen Group, or Ipsen, including Interim Chief Financial Officer, Deputy Chief Financial Officer, member of Ipsen’s Executive Committee and other positions in the administration and finance department and participated in various external growth operations and creation of Ipsen’s investor relations function. From 2003 to 2006, Mr. Schilansky spent three years at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations. From 1999 to 2002, he spent three years at Warburg Dillon Read (now UBS Investment Bank) in the field of mergers and acquisitions. Mr. Schilansky received a Master degree from Université de Paris Dauphine and a Master degree from Imperial College in London.
Mr. Charles Ruban has been Chief Commercial Officer since January 20, 2016. Mr. Ruban served as Senior Executive Vice President of Clinical Development & North American Operations since January 2015 until January 20, 2016. Charles Ruban has served as Chief Development Officer since June 2012 and oversees all development activities including clinical operations, medical affairs, non clinical development, regulatory affairs and pharmaceutical development. He is a member of the Executive Committee. From 2003 to 2012, Mr. Ruban held various executive positions at Stallergènes S.A., including Senior Vice President of Product Development, member of the Executive Committee, Director of Research & Development Program and Director of Supply Chain. From 1994 to 2003, Mr. Ruban spent nine years at Eurogroup Consulting as a management consultant. Mr. Ruban received an Engineering degree from the Ecole Centrale de Lyon, trained at Harvard-MIT Division of Health Sciences and Technology for his Master of Science in Biomedical Engineering and graduated with an Executive MBA from INSEAD.
PharmD from the Université René Descartes in Paris with an M.B.A. from IAE Paris Sorbonne and a Master of Law in Public Health from the faculty of Sceaux, Laurent Martin joined DBV Technologies with more than 15 years of experience in the pharmaceutical industry. He has extensive experience in the management of international pharmaceutical development projects in Europe and the United States and in marketing authorization applications, particularly in Europe with the European Medicines Agency (EMA) via the centralized procedure. He acquired his expertise in regulatory affairs through various pharmaceutical companies, such as Galderma, Guerbet, and finally, Orphan Europe, a company specialized in the development and marketing of orphan drugs, in which his last position was as Interim Responsible Pharmacist (Qualified Person), Manager of Pharmaceutical and Pre-Clinical Development, and Quality Assurance Manager. Mr Laurent Martin has been Chief Development Officer since January 20, 2016. He elaborates all the regulatory strategy of the products being developed, coordinates the regulatory filings related to the clinical studies and the international registration of the drugs of DBV Technologies. He is also Director of Quality.
Dr. Lucia Septién
Dr. Septién has more than 20 years of experience in the pharmaceutical industry, where she has a strong track record in drug development and medical affairs. She has held several senior positions, leading R&D and Portfolio Management Strategy teams in a wide range of therapeutic areas, including small molecules and biologicals. Dr. Septién spent most of her career at Pfizer and Wyeth. At Pfizer, she served as Vice President of the Specialty Care Business Unit, Europe, where she led a team of over 300 staff providing medical and scientific support in several therapeutic areas, including immunology, vaccines, inflammation, and rare diseases. Prior to Pfizer, Dr. Septién served at Wyeth Pharma as Assistant Vice President, Global Neuroscience, responsible for major Phase II and III development programs, including the clinical studies of monoclonal antibodies in Alzheimer's disease in over 27 countries. Lucia also contributed to several product registrations with both the U.S. Food and Drug Administration and the European Medicines Agency. Prior to joining DBV, Lucia was Vice President, Global Neurosciences, responsible for the Medical Strategy of the Botulinum Toxin portfolio at Ipsen. Lucia earned her medical degree and specialized in Psychiatry at the National University of Mexico City. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l'Energie Atomique in Saclay, France.
Pr. Hugh Sampson
Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA, appointed as Chief Scientific Officer of DBV in June 2015. He is Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson's research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of food-induced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the National Institutes of Health (NIH) and private foundations. He is the Principal Investigator of the NIH-sponsored Consortium of Food Allergy Research (CoFAR). He is also former President of the American Academy of Allergy Asthma and Immunology (AAAAI).